Strategy to avoid local recurrence in patients with locally advanced rectal cancer
暂无分享,去创建一个
[1] Masaaki Ito,et al. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial , 2017, Annals of surgery.
[2] J. Lim,et al. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. , 2015, International journal of radiation oncology, biology, physics.
[3] R. Beart,et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. , 2015, Journal of the National Cancer Institute.
[4] T. Hothorn,et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[5] Joon-Oh Park,et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. , 2014, The Lancet. Oncology.
[6] K. Yamashita,et al. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. , 2014, International journal of radiation oncology, biology, physics.
[7] J. Park,et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. , 2014, The Lancet. Oncology.
[8] T. Beißbarth,et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Gonen,et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Collette,et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. , 2014, The Lancet. Oncology.
[11] H. Kuroyanagi,et al. Laparoscopic surgery for rectal cancer: Current status and future perspective , 2014, Asian journal of endoscopic surgery.
[12] S. Larson,et al. Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study , 2013, Annals of surgery.
[13] T. Conroy,et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] W. Hohenberger,et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Hein Putter,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.
[16] K. Yamashita,et al. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. , 2011, International journal of radiation oncology, biology, physics.
[17] N. Petrelli,et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] I. Okayasu,et al. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. , 2007, International journal of radiation oncology, biology, physics.
[19] L. Påhlman,et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Macfarlane,et al. Mesorectal excision for rectal cancer , 1993, The Lancet.
[21] T. Muto,et al. Selective Lateral Pelvic Lymph Node Dissection in Patients with Advanced Low Rectal Cancer Treated with Preoperative Chemoradiotherapy Based on Pretreatment Imaging , 2013, Annals of Surgical Oncology.
[22] O. Dworak,et al. Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.